Document is current
Any future updates will be listed below
-
Authors
Telenti, Amalio https://orcid.org/0000-0001-6290-7677
Arvin, Ann https://orcid.org/0000-0001-5404-1498
Corey, Lawrence https://orcid.org/0000-0002-2179-2436
Corti, Davide https://orcid.org/0000-0002-5797-1364
Diamond, Michael S. https://orcid.org/0000-0002-8791-3165
García-Sastre, Adolfo https://orcid.org/0000-0002-6551-1827
Garry, Robert F.
Holmes, Edward C. https://orcid.org/0000-0001-9596-3552
Pang, Phillip S. https://orcid.org/0000-0002-8811-9801
Virgin, Herbert W. https://orcid.org/0000-0001-8580-7628
- License Information
-
More Information
Article History
Received: 12 May 2021
Accepted: 1 July 2021
First Online: 8 July 2021
Competing interests
: A.T., A.A., D.C., P.P. and H.W.V. are employees of Vir Biotechnology Inc. and may hold shares in Vir Biotechnology Inc. L.C., M.S.D. and E.C.H. are co-founders or consultants of Vir Biotechnology Inc. The Diamond laboratory at Washington University School of Medicine has received sponsored research agreements from Moderna and Vir Biotechnology. The García-Sastre laboratory has received research support from Pfizer, Senhwa Biosciences and 7Hills Pharma. A.G.-S. has consulting agreements for the following companies involving cash and/or stock: Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Vaxalto, Accurius and Esperovax. R.F.G. is co-founder of Zalgen Labs, a biotechnology company that develops countermeasures to emerging viruses.
Free to read: This content has been made available to all.
